Tema Etfs LLC Purchases Shares of 10,626 Insmed Incorporated (NASDAQ:INSM)

Tema Etfs LLC purchased a new position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 10,626 shares of the biopharmaceutical company's stock, valued at approximately $734,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Park Avenue Securities LLC lifted its holdings in shares of Insmed by 42.1% in the 4th quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company's stock worth $549,000 after purchasing an additional 2,358 shares in the last quarter. Atomi Financial Group Inc. raised its holdings in Insmed by 6.6% during the fourth quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company's stock worth $1,710,000 after buying an additional 1,526 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Insmed by 5.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock valued at $244,000 after buying an additional 183 shares in the last quarter. Avior Wealth Management LLC acquired a new position in shares of Insmed during the fourth quarter valued at about $157,000. Finally, Blue Trust Inc. lifted its holdings in shares of Insmed by 25.7% in the fourth quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company's stock valued at $180,000 after purchasing an additional 503 shares in the last quarter.

Insider Activity

In other Insmed news, insider Martina M.D. Flammer sold 1,799 shares of Insmed stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $67.53, for a total value of $121,486.47. Following the transaction, the insider now directly owns 84,797 shares of the company's stock, valued at $5,726,341.41. The trade was a 2.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares of the company's stock, valued at approximately $25,742,347.58. This trade represents a 5.31% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 125,211 shares of company stock valued at $8,837,158. Insiders own 3.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on INSM shares. Jefferies Financial Group assumed coverage on Insmed in a report on Tuesday, May 13th. They set a "buy" rating and a $105.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $90.00 price objective on shares of Insmed in a report on Monday, May 12th. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Morgan Stanley increased their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Finally, UBS Group lowered their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $94.63.

Insmed Price Performance

Shares of INSM stock traded down $2.49 on Wednesday, reaching $66.02. The company's stock had a trading volume of 2,144,969 shares, compared to its average volume of 2,331,073. The stock's 50 day simple moving average is $71.11 and its 200-day simple moving average is $73.08. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The company has a market capitalization of $12.02 billion, a P/E ratio of -11.81 and a beta of 0.84. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same quarter in the previous year, the company posted ($1.06) earnings per share. Insmed's revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, equities analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.